Transplantation therapeutics Global Market Forecast

1

• Transplantation therapeutics Global market
  Research Report Ken Research

2

• Frontier Pharma Transplantation Therapeutics-A
  Highly Innovative Pipeline with a Range of
  Adaptive and Innate Immune-Targeting Programs
  Focusing on Graft-Versus-Host Disease and Kidney
  Transplantation
• In 2015 a total of 127,000 transplantations were
  performed worldwide, an increase of 5.8 from
  2014, with 33,000 of these occurring in the EU
  and 32,000 in the US. Approximately 60 of these
  were kidney transplants, with liver, heart, lung,
  pancreas and small bowel transplantations
  accounting for the other most common procedures
  (Dominguez-Gil and Matesanz, 2017). When a graft
  is transplanted from a genetically non-identical
  individual, the recipients immune system
  recognizes the graft as foreign.

3

• This leads to an anti-graft immune response that
  involves T cells invading the new tissue,
  multiplying, and recruiting more immune cells to
  the transplant site in order to remove this
  foreign body. Depending on the nature of the
  incompatibility and the immune response, and
  acute or chronic rejection process can occur.
  Conversely, if the graft consists of
  hematopoietic stem cells or immune cells, there
  is a risk that they will mount an immune response
  against the host, known as graft versus host
  disease (GVHD). There are several safe
  pharmacological treatment options for acute
  rejections, but long-term treatment options
  remain unsatisfactory.

4

• The risk of infection limits the effectiveness of
  these therapies, and improvements to their
  efficacy are also needed. Specific
  transplantation tolerance, in which alloreactive
  T cells are inactivated while the broader immune
  response is left intact, removing the need for
  broad immunosuppressant therapies, can be
  considered to be the ultimate goal for clinical
  transplantation. Compared with the overall
  immunology pipeline, in which there are 1,915
  products, the transplantation pipeline is small,
  with only 244 products. However, of the 145
  products in the transplantation pipeline with a
  disclosed molecular target, there are 65
  first-in-class products, acting on a total of 63
  distinct first-in-class targets, highlighting the
  fact that this pipeline displays strong levels of
  innovation.

5

• There is a need for therapies that can achieve
  graft-specific immunosuppression, without having
  a general effect on the wider immune system.
  Which therapies and technologies currently in
  development are most likely to achieve this?
  There are 63 distinct first-in-class molecular
  targets in development for transplantation. Which
  of these hold the strongest potential in the
  clinic, and which are closest to reaching the
  market? How effective are current therapies for
  these indications, and how have they been able to
  improve the general prognosis in recent decades?
  Which molecule types and molecular targets are
  most prominent across transplantation therapy?
  Which specific types of transplantation are being
  most heavily studied across the pharmaceutical
  pipeline?

6

• Appreciate the current clinical and commercial
  landscapes by considering disease symptoms,
  pathogenesis, etiology, co-morbidities and
  complications, epidemiology, diagnosis, prognosis
  and treatment options for transplantation
  rejection. Identify leading products and key
  unmet needs within the market. Recognize trends
  in pipeline innovation by analyzing therapies by
  stage of development, molecule type and molecular
  target. Assess the therapeutic potential of
  first-in-class targets. Using a proprietary
  molecular target matrix assessment,
  first-in-class targets in the pipeline have been
  assessed and ranked according to clinical
  potential. Consider first-in-class pipeline
  products with no prior involvement in licensing
  and co-development deals, which may represent
  potential investment opportunities.

7
Key topics covered in the Report-

• Transplantation therapeutics Global Market
  Research Report
• Transplantation therapeutics Global Market Size
• Transplantation therapeutics Global Report
• Transplantation therapeutics Global Market
• Transplantation therapeutics Global Analysis
• Transplantation therapeutics Global Market
  Forecast
• Transplantation therapeutics Global Market Major
  Players
• Transplantation therapeutics Global Market
  Forecast
• Transplantation therapeutics Global Market
  Analysis
• Transplantation therapeutics Global Leading
  Competitors

8

• To know more, click on the link below
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/frontier-pharmatransplantation-therapeutics/1
  42624-91.html
• Related Reports-
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/stem-cell-transplantation-global-clinical-tri
  als-review-h2-2016/65249-91.html
• https//www.kenresearch.com/healthcare/pharmaceuti
  cals/transplantation-global-clinical/9033-91.html
•  
• Contact Us
• Ken Research
• Ankur Gupta, Head Marketing Communications
• sales_at_kenresearch.com
• 0124-4230204
•  
•  

9
(No Transcript)